Healthscope acquisition one step closer after Federal Court approval

The Healthscope Limited (ASX: HSO) share price could see higher trading volume this morning after it announced it had received court approval to vote on its proposed takeover by Brookfield.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healthscope Limited (ASX: HSO) share price could see higher trading volume this morning after it announced it had received court approval to vote on its proposed takeover by Brookfield.

a woman

What did Healthscope announce yesterday?

Healthscope announced that the Federal Court has ordered a meeting of Healthscope shareholders to consider and vote on the previously announced scheme of arrangement regarding Brookfield's acquisition of all Healthscope shares.

The Federal Court order follows Brookfield's receipt of all regulatory approvals for the deal contemplated under the Implementation Deed.

If the scheme is approved by the required majority of Healthscope shareholders and all relevant conditions satisfied or waived, Healthscope shareholders will receive cash consideration of $2.465 per Healthscope share to be paid on the implementation date (currently slated for 6 June 2019).

The Healthscope Board continues to unanimously recommend that Healthscope shareholders:

  • Vote in favour of the scheme
  • Accept the takeover offer for all Healthscope shares owned, and
  • Vote in favour of the capital return

Which S&P/ASX200 shares would I be investing in?

Given Healthscope's shares are currently trading at $2.46 per share, I wouldn't expect the share price to move at all provided the Brookfield deal is approved.

Instead, I'd be checking out the likes of Appen Ltd (ASX: APX) or Afterpay Touch Group Ltd (ASX: ALU) which have been soaring higher so far in 2019.

Afterpay has continued to be one of the top performers in the S&P/ASX200 Index (ASX: XJO) in 2019 and its share price growth has been fuelled by favourable Senate inquiry findings and a successful international expansion.

While the company currently generates its revenue in the form of a fee or "spread" from its retail merchant partners, the real value in Afterpay remains its future potential as a data organisation.

With targeted information on each demographic and their spending habits, Afterpay represents an advertiser's dream and the ability to monetise this significant dataset in an ethical and profitable manner is the key to the business' future success.

For those who want to look for growth outside of the mining sector, this top-rated stock could boost portfolio gains as it continues to soar in a $22 billion industry.

Motley Fool contributor Lachlan Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of AFTERPAY T FPO and Appen Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »